Dr. Hamid Abbasi performs a new kind of back surgery that he promotes as offering great results with minimal physical trauma.
The website for his busy neurosurgery practice in Alexandria, Minn., explains that the procedure requires only a small incision and leads to less blood loss than other approaches. Some patients go home the same day, Abbasi says in a video presentation.
There's another benefit for Abbasi: He has received some of the profits from some of his patients' devices, because he's an investor in the distributor that sells them to hospitals. Federal records show that during five months in 2013 the company distributed at least $365,325 in physician payouts — one of the largest sums of its kind in the nation during that period.
This arrangement is among the thousands of financial relationships between doctors and health care companies coming to light through a new federal database that enables the public to see if a physician is profiting by using a certain product. Federal regulators have long been critical of these kinds of arrangements, and Sen. Chuck Grassley, R-Iowa, said he co-authored the bill to create the database partly so the public could scrutinize them.
"These are very significant financial relationships," said Dr. Michael Carome, a former federal health care safety regulator who now directs health research at the Washington advocacy group Public Citizen. "Such relationships could … cause a physician to recommend a particular product, not because they think it's best for the patient, but because they have a financial interest."
The new Open Payments data from the Centers for Medicare and Medicaid Services (CMS) cover many types of financial relationships besides investments, such as consulting deals, free travel for conferences and straight gifts. The disclosure program was created as part of the Affordable Care Act to shed light on hidden financial relationships in medicine — a topic of national urgency as health care consumes a growing share of government, business and household budgets.
The line between relationships that advance the practice of medicine and those that simply advance drug and device companies' interests is blurry. Medicare's fiscal watchdog has warned that some situations create a clear risk of illegalities under the federal Anti-Kickback Statute, which generally outlaws payments that induce or reward someone to refer patients for treatments under government insurance programs.
But defenders of financial relationships between companies and doctors say such collaboration expands access to treatment and benefits patients.